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Abstract: Antibiotic cross-reactivity represents a phenomenon of considerable interest as well as
antibiotic resistance. Immediate reactions to cephalosporins are reported in the literature with
a prevalence of only 1–3% of the population, while anaphylactic reactions are rarely described
(approximately 0.0001–0.1%) as well as fatalities. Allergic reaction to cephalosporins may occur
because of sensitization to unique cephalosporin haptens or to determinants shared with penicillins.
Cross-reactivity between cephalosporins represents, in fact, a well-known threatening event involving
cephalosporins with similar or identical R1- or R2-side chains. The present report describes the
case of a 79-year-old man who suddenly died after intramuscular administration of ceftriaxone.
Serum dosage of mast cell tryptase from a femoral blood sample at 3 and 24 h detected values of
87.7µg/L and 93.5µg/L, respectively (cut-off value 44.3 µg/L); the serum-specific IgE for penicillins,
amoxicillin, cephaclor and also for the most common allergens were also determined. A complete
post-mortem examination was performed, including gross, histological and immunohistochemical
examination, with an anti-tryptase antibody. The cause of death was identified as anaphylactic shock:
past administrations of cefepime sensitized the subject to cephalosporins and a fatal cross-reactivity
of ceftriaxone with cefepime occurred due to the identical seven-position side chain structure in both
molecules. The reported case offers food for thought regarding the study of cross-reactivity and the
need to clarify the predictability and preventability of the phenomenon in fatal events.
Keywords: anaphylactic shock; ceftriaxone; cefepime; immunohistochemistry; liability; medical
malpractice; R1 side-chain; R2 side-chain
1. Introduction
Antibiotic allergy is defined as an immunologically mediated drug hypersensitivity reaction,
either IgE- or non-IgE-mediated [1], and represents the most common cause of hypersensitivity (HSRs)
and adverse drug reactions (ADRs) [2].
ADRs differ from adverse drug events (ADEs), as ADEs extend beyond ADRs to include injury
resulting from medical errors [3]: ADEs are largely preventable and include medication errors, adverse
drug reactions, allergic reactions and overdoses [4]. In hospitalized patients, antibiotic related-ADRs
are associated with inferior clinical outcomes: microbiological resistance, restricted antibiotic use,
adverse events, increased readmissions and excess mortality [5,6]. In the general population, antibiotics
represent the commonest cause of life-threatening immune-mediated drug reactions that are considered
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off-target, where “off-target” is defined as being caused by different mechanisms of action rather
than the intended primary pharmacologic mechanism [7]. Life-threatening drug reactions include
anaphylaxis, organ-specific reactions and severe cutaneous adverse reactions (SCARs) [8].
Approximately 10% of the population is known to be antibiotic-allergic [9], so such reactions
pose undeniable risk to patients, and addressing antibiotic allergy reactions currently represents a
significant public health issue [10].
Penicillins, cephalosporins, monobactams and carbapenems (betalactam antibiotics, with a similar
structure to a beta-lactam ring) are recognized as one of the most common causes of immediate (within
one hour) and delayed (after 72 h) adverse drug reactions (ADRs), mediated by specific immunological
mechanisms (IgE and non-IgE-mediated).
Immediate reactions to cephalosporins are reported in the literature with a prevalence of only
1–3% of the population: these reactions generally occur within one hour from administration,
with symptoms represented mainly by urticarial, rhinitis and bronchospasm. Increasing serum
IgE for cephalosporins is also observed: in most cases it is an idiopathic mechanism, without
contraindications for future use of cephalosporins. On the other hand, anaphylactic shock is rarely
described (approximately 0.0001–0.1%) as well as fatalities [11,12], in subjects with beta-lactam allergies.
In particular, anaphylactic reactions following the administration of specific cephalosporins are reported
and related to penicillins–cephalosporins’ or cephalosporins’ cross-reactivity [13].
Cross-reactivity between penicillins and first- and second-generation cephalosporins has been
reported in 10% of penicillin-allergic patients. However, older studies may have overstated the
cross-reactivity as the first cephalosporins contained traces of penicillins [14]. Cross-reactivity between
penicillins and third-generation cephalosporins occurs in 2–3% of patients allergic to penicillins [15–17].
Cross-reactivity between cephalosporins can cause immune-mediated reactions in 1–3% of patients,
even in the absence of a history of penicillin allergy [18].
As a consequence, prescription of antibiotics in subjects with known IgE-mediated hypersensitivity
to beta-lactams is a big concern and the tolerability of an alternative cephalosporin is still debated.
The risk for patients with a beta-lactams allergy is to receive suboptimal therapy, experience clinical
failure, develop drug-resistant organisms and to have prolonged hospitalization and higher in-hospital
mortality [19–22]. Common clinical practice suggests avoiding other beta-lactams in patients with a
labeled beta-lactams allergy. Pre-treatment skin tests with alternative cephalosporins have also been
proposed but doubts about validity still remain [23,24].
2. Case Report
A 79-year-old man suddenly died after intramuscular administration of ceftriaxone prescribed
by a general practitioner (GP) because of cutaneous abscess. Dyspnea, cyanosis and cardiac arrest
occurred immediately after administration and resuscitation maneuvers were unsuccessful. In the
medical history, recurrent chronic obstructive pulmonary disease (COPD) exacerbations were recorded
with antibiotic treatments in the last ten years, as described in Table 1. An episode of sudden lipothymia
after administration of cefepime was also reported ten months before death and recorded as an allergic
reaction in the electronic GP medical record. After death, medical malpractice of the GP was reported,
and the day after death a complete post-mortem examination was ordered by the prosecutor.
Before the autopsy investigation, dosage of serum tryptase levels was performed on blood samples,
sampled 3 h and 24 h after death and frozen at −20 ◦C. Serum tryptase levels were determined by EliA
test based on fluorescence enzyme immunoassay (FEIA) (ImmunoCap Tryptase, Phadia 250: Thermo
Fisher Scientific, Phadia AB, Uppsala Sweden). Serum dosage of β-tryptase from femoral blood
detected values of 87.7 µg/L and 93.5 µg/L respectively (cut-off value 44.3 µg/L [25]). Serum-specific IgE
for penicillins, amoxicillin, cephaclor and also for the most common allergens were also determined
on the cadaveric blood samples by EliA test, based on fluorescence enzyme immunoassay (FEIA)
(ImmunoCAP Allergen Components, Phadia 250: Thermo Fisher Scientific, Phadia AB, Uppsala
Sweden), as reported in Table 2.
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The external examination was normal except for a cutaneous abscess localized in the right gluteus.
The internal examination was unremarkable except for heavy lungs and abundant reddish-colored
foam on the main bronchi. The other organs did not show any specific pathological alterations except
for cerebral edema.
Table 1. Schedule of antibiotics administration over a wide range of time (ten years).
DOP 1 ROA 2 Antibiotic
05.02.2003 i.m. 1 fl 1 gr Ceftazidime
15.09.2006 cpr 500 mg Ciprofloxacin
03.11.2006 i.m. 1 gr Ceftriaxone
24.11.2006 os 875 mg + 125 mg Amoxicillin + Clavulanic acid
05.05.2008 cps 400 mg Ceftibuten
09.06.2008 i.m. 1 fl 2 gr Piperacillin + Tazobactam
09.06.2008 cpr 500 mg Levofloxacin
15.12.2010 im 1 fl 1 gr Ceftriaxone
17.12.2010 im 1 fl 1 gr Ceftriaxone
30.12.2010 cpr 750 mg Ciprofloxacin
31.01.2011 cpr 750 mg Ciprofloxacin
23.02.2011 im 1 fl 1 gr Cefepime
04.04.2011 cpr 875 mg Amoxicillin + Clavulanic acid
10.11.2011 cpr 750 mg Ciprofloxacin
09.02.2012 cpr riv 500 mg Ciprofloxacin
20.02.2012 cpr 500 mg Levofloxacin
06.04.2012 i.m. 1 fl 1 gr Cefepime *
06.04.2012 cpr 750 mg Ciprofloxacin
19.04.2012 cpr 875 mg Amoxicillin + Clavulanic acid
19.04.2012 cpr 500 mg Levofloxacin
06.11.2012 i.m. 1 fl 2 gr Piperacillin + Tazobactam
06.11.2012 cpr 750 mg Ciprofloxacin
12.11.2012 cpr 750 mg Ciprofloxacin
06.12.2012 cpr 750 mg Ciprofloxacin
03.01.2013 i.m. 1 fl 2 gr Piperacillin + Tazobactam
03.01.2013 cpr 750 mg Ciprofloxacin
18.02.2013 i.m. 1 fl 1 gr Ceftriaxone
18.02.2013 cpr 875 mg Amoxicillin + Clavulanic acid
* In these circumstances, a lipothymia-like episode occurred immediately after administration. 1 DOP: date of
prescription. 2 ROA: route of administration.
Table 2. Fluorescence enzyme immunoassay (FEIA) of blood samples collected 3 h and 24 h after
death for detection of specific IgE for penicillins, ampicillin, amoxicillin, cephaclor and for the most
common allergens.
Allergens Blood—3 h After Death * Blood—24 h After Death *
c1 (Penicillin G) 1.08 0.26
c2 (Penicillin V) 3.47 1.57
c5 (Ampicillin) 1.33 0.45
c6 (Amoxicillin) 1.26 0.26
c7 (Cefaclor) 1.36 0.53
g6 (Timothy grass-Phleum pratense) 1.75 0.55
t9 (Olive-Olea europaea) 1.20 0.27
t23 (Cypress-Cupressus sempervirens) 1.28 0.28
f1 (Egg) 1.97 0.83
f2 (Milk) 1.67 0.46
d1 (Dermatophagoides pteronyssinus) 1.31 0.33
* kUA/mL.
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All tissue specimens were fixed in formalin and embedded in paraffin, and a routine microscopic
histopathological study was performed using hematoxylin-eosin (H&E). Acute polivisceral stasis,
mild cerebral edema and interstitial myocardial edema were observed. Chronic and acute pulmonary
emphysema, as well as massive pulmonary edema, were observed in all samples.
An immunohistochemical investigation to assess the mast-cell population was performed using
antibodies anti-tryptase for lung sections. Enzyme pre-treatment with proteinase K (0.01% at 37 ◦C)
was necessary to facilitate antigen retrieval and to increase membrane permeability to antibodies.
The primary antibody anti-tryptase (Agilent-Dako, Santa Clara, CA, USA) was applied at a 1:100 ratio
and incubated overnight at 4 ◦C. The positive reaction was visualized by 3-amino-9ethyl-carbazole
(AEC) (Sigma-Aldrich Merck, Darmstadt, Germany). The sections were counterstained with Mayer’s
hematoxylin and mounted in Aquatex (Merck Pharma, Darmstadt, Germany). A quantitative analysis
was performed in each histological section, with 10 observations in different fields per slide equivalent
to 70 observations. The positive mast-cell count to the tryptase reaction was made at a magnification
of 10× using a light microscope coupled to a high-resolution color video camera: a pulmonary
area of 100 mm2 was analyzed. Pulmonary mast cells were identified and quantified, and a great
number of degranulating mast cells with tryptase-positive material outside were observed (Figure 1).
Data resulting from quantitative analysis recorded a numerical increase in pulmonary mast cells
(average mast-cell count 11,951/100 mm2) compared with a control group represented by traumatic
deaths (average mast-cell count 3557/100 mm2).
Toxicological analysis on urine and blood specimens was performed using gas
chromatography-mass spectrometry (GC-MS) and resulted negative.
A fatal anaphylactic shock was recorded as the cause of death: it was supposed that past
administration of cefepime with lipothymia sensitized the subject to cephalosporins and a fatal
cross-reactivity between ceftriaxone and cefepime, sharing a similar seven-position side chain, occurred.
The court excluded medical malpractice of the GP because of the high degree of knowledge required
to discriminate between cephalosporins with similar or identical R-side chains and the difficulty to
predict cross-reactivity before administration beyond reasonable doubt.
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3. Discussion
Cephalosporins represent one of the most commonly prescribed classes of antibiotics for pulmonary,
skin and soft tissue infections due to their broad spectrum of activity and low toxicity profile.
Anaphylactic reactions from cephalosporins are extremely rare and the incidence of allergy is estimated
to be 1–3% of the general population [26,27]. A French report in 2005 described a 27% prevalence of
severe allergic reactions to cephalosporins among all cases involving β-lactams [28].
Cross-reactivity between cephalosporins and penicillins has been widely investigated in the past
and the safety of cephalosporins’ prescription in patients primarily sensitized to penicillins has been
deeply analyzed [29]. Recent data suggest that 1–4% of patients with a history of penicillin allergy have
a true cephalosporin allergy. Skin manifestations (1–5%), fever (0.5–0.9%), eosinophilia (2–10%) and
anaphylaxis (<0.1%) are the most commonly reported clinical signs in case of cephalosporin allergies [26].
In other studies, the incidence of anaphylaxis to cephalosporins is estimated as 0.0001–0.1% [30].
Cross-reactivity between cephalosporins has been less studied than the reaction to cephalosporins
in patients with primary sensitization to penicillins. While the chemical structure of the allergenic
determinants of penicillins is known, the allergenic determinants of cephalosporins have not been
completely elucidated. Thus, standardized diagnostic tests for cephalosporin allergy are not
available [31].
Some studies have demonstrated that cephalosporins generate unique structures capable of
provoking an IgE-mediated immunologic response [32]. Cephalosporins consist of a six-membered
dihydrothiazine ring fused to a core, four-membered cyclic amide beta-lactam ring with two side chains,
R1 and R2. The chemical structure of cephalosporins differs significantly in side chains bound to the R
sites. These differences explain variation in the spectrum of activity and duration of action of individual
cephalosporins grouped into five generations. Both the R1- and the R2-side chains may contribute to
the configuration of different epitopes [33]. When IgE antibodies react with cephalosporins, they may
recognize a portion of a side chain, the methylene group, full-side chains, a combination of a side chain
and part of the beta-lactam ring and even the entire cephalosporin molecule [14,34–36].
Wide evidence exists about aminobenzyl R1-side chains of cephalosporins’ involvement in
allergic reactions, so that it is often considered the only allergenic structure of cephalosporins.
Cross-reactivity between cephalosporins represents, in fact, a well-known threatening event involving
cephalosporins with similar or identical R1-side chains [37] (Scheme 1). Cross-reactivity between
ceftriaxone, cefuroxime, cefotaxime and cefozidime has been widely investigated, because of identical
(ceftriaxone and cefotaxime) or similar (ceftazidime) R1-side chains. In particular, identical R1-side
chains were demonstrated in cases of cross-reactivity between ceftriaxone and cefotaxime [38]. In other
cases, even slight differences in the R1 side chain should make IgE-mediated reactions unexpected [39]:
Pichichero observed cephalosporins that share a similar seven-position or three-position side chain are
more likely to cross-react with each other [11].
Additionally, R2-side chains’ involvement cannot be excluded, and nor can a combined effect of
R2-side chains with the R1 methoxymino (Table 3). The rupture of the dihydrothiazine ring occurring
during cephalosporin degradation leads to the expulsion of the R2 group while the R1 group remains
intact [37,40–42]. Additionally, immediate hypersensitivity was reported between cefoperazone and
cefamandole sharing an identical R2-side chain [43].
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Table 3. Cephalosporins sharing identical or similar R2-side chains.
Exact R2-Side Chains Similar R2-Side Chains
Cefazolin Ceftezole
Cefepime Cefiderocol
Cefiderocol Cefepime
Cefixime Cefdinir
Cefmandole foperaz ne, Cephapir n Cefuroxime
Cefonicid Cefmandole, Cefoperazone, Cefotetan
Cefotaxime Cephalotin, Cephapirin Cefuroxime
foxiti Cefuroxime Cefotaxime, Cefoxitin, Cephapirin
efpiron Ceftazidime
Ceftez le C fazolin
Cefuroxime Cefoxitin Cefotaxime, Cephalotin, Cephapirin
Cephalotin Cephapirin Cefoxitin, Cefuroxime
Lastly, in other cases, a selective hypersensitivity to individual cephalosporins without
cross-reactivity has been reported, suggesting that the entire cephalosporin molecule could be involved
in reactions [44].
Hypersensitivity reactions to cephalosporins generally occur within 24 h of drug exposure and
consist of cutaneous rashes [26]. Despite the rarity of fatal events, worries regarding prescriptions and
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litigation surfaced early [38,45,46]. In fact, the evaluation of patients with primary hypersensitivity to
β-lactams and cephalosporins is often not sufficiently addressed and the risk of litigation is high [47–50].
In patients with a true IgE-mediated reaction to cephalosporin, substituting cephalosporins to
avoid allergy is mandatory and knowledge of the similarities and differences between R1 groups and
R2 groups must be necessarily requested to avoid threatening consequences for patients. In particular,
considering side-chain groups for the prescription of cephalosporins in a subject with previous
IgE-mediated hypersensitivity to these beta-lactams is considered of paramount importance [51]:
in these cases, cephalosporins with dissimilar side chains should be prescribed.
Despite the valuable results of skin tests, used to diagnose immediate hypersensitivity to
cephalosporins, the limitations must be clearly considered [52]. The rate of positive skin tests to
cephalosporins in patients with a history of confirmed hypersensitivity reactions varies sensitively from
0.3% to 69.7% [46,53]. A negative predictive value of skin tests of 82% was estimated [54]. Additionally,
routine screening with an intradermal test with cephalosporin prior to administration does not predict
immediate hypersensitivity and it can lead to false drug allergy labelling [55,56].
Before the administration of cephalosporin in a patient with known hypersensitivity to
cephalosporins, induction of drug tolerance or graded challenge procedures may be taken in
account [31].
4. Conclusions
The reported case enhances the value of a detailed history in cases of suspected cephalosporin
allergy. Symptoms, the class of cephalosporin involved in primary hypersensitivity, the R-group side
chain, the route of administration and previous reactions to penicillins or other cephalosporins should
be investigated. The implementation of reporting systems and further research are desirable to reduce
the incidence of adverse drug reaction and improve administration safety. Such an effort could allow
the individualization of future antibiotic therapies, that should be tailored on the basis of potential
cross-reactions [57,58].
In the reported case, the court assigned sharing of identical or similar R1- and R2-side chains of
cephalosporins in the sphere of the “high degree” of knowledge not requirable to general practitioners.
The difficulty to predict cross-reactivity before administration beyond a reasonable doubt acted in
favor of the GP.
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